Literature DB >> 7834217

Mediation by SRIF1 receptors of the contractile action of somatostatin in rat isolated distal colon; studies using some novel SRIF analogues.

E S McKeen1, W Feniuk, P P Humphrey.   

Abstract

1. The motor effects of somatostatin-14 (SRIF), and several SRIF peptide analogues were investigated on the rat isolated distal colon. The objective of these studies was to characterize the receptor mediating the contractile action of SRIF by comparing the relative agonist potencies of a range of SRIF analogues. 2. SRIF (1 nM-1 microM) produced concentration-dependent contractions with an EC50 value of approximately 10 nM. Contractile responses induced by SRIF were insensitive to atropine (1 microM) or naloxone (1 microM) but abolished by tetrodotoxin (1 microM). Somatostatin-28 (SRIF28), also induced concentration-dependent contractions and was equipotent with SRIF. Phosphoramidon (1 microM) and amastatin (10 microM) did not increase the potency of either SRIF or SRIF28. 3. The SRIF peptide analogues, octreotide, SRIF25, seglitide, angiopeptin and CGP23996 (1 nM-1 microM) produced contractile responses in the rat distal colon, each having similar potency and maximal activity relative to SRIF. The SSTR2 receptor-selective hexapeptide, BIM23027 (0.1 nM-1 microM), and the SRIF stereoisomer, D-Trp8-SRIF (0.1 nM-1 microM), were the most potent agonists examined being approximately 12 and 7 times more potent than SRIF, respectively. In contrast, the SSTR5 receptor-selective analogue, L362,855, was approximately 120 times weaker than SRIF, whilst the SSTR3 receptor-selective analogue, BIM23056, was inactive at concentrations up to 3 microM. 4. The putative SRIF receptor antagonist, (cyclo(7-aminoheptanoyl Phe-D-Trp-Lys-Thr[Bzl]))(CPP) (1 microM), had no agonist activity and had no effect on contractions induced by SRIF. 5. The contractile actions of BIM23027 and seglitide were subject to pronounced desensitization. Desensitization of preparations by BIM23027 (0.3 JIM) abolished the contractile action of SRIF andSRIF28 but had no effect on contractions produced by acetylcholine (0.1 nM-I1M), suggesting thatBIM23027, SRIF and SRIF28 act via a common receptor mechanism.6. In conclusion, the rat isolated distal colon contracts in response to SRIF and a number of SRIF analogues. Seglitide and octreotide exhibited similar potency and maximal activity relative to SRIF,suggesting that in the rat colon the receptor mediating contraction belongs to the SRIF,-receptor group,of which the recombinant SSTR2, SSTR3 and SSTR5 receptors appear to be subtypes. The high potency of BIM23027, the weak agonist activity of L362,855 and the lack of activity exhibited by BIM23056suggests that the SRIF receptor mediating contraction in the rat distal colon is similar to there combinant SSTR2 receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7834217      PMCID: PMC1510125          DOI: 10.1111/j.1476-5381.1994.tb17036.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptors.

Authors:  L Terenius
Journal:  Eur J Pharmacol       Date:  1976-07       Impact factor: 4.432

2.  Comparison of the gastric exocrine inhibitory activities and plasma kinetics of somatostatin-28 and somatostatin-14 in cats.

Authors:  B H Hirst; J M Conlon; D H Coy; J Holland; B Shaw
Journal:  Regul Pept       Date:  1982-09

3.  High biological activity of the synthetic replicates of somatostatin-28 and somatostatin-25.

Authors:  P Brazeau; N Ling; F Esch; P Böhlen; R Benoit; R Guillemin
Journal:  Regul Pept       Date:  1981-01

4.  An immunohistochemical study of the projections of somatostatin-containing neurons in the guinea-pig intestine.

Authors:  M Costa; J B Furness; I J Smith; B Davies; J Oliver
Journal:  Neuroscience       Date:  1980       Impact factor: 3.590

5.  Synthesis and biological actions of prosomatostatin.

Authors:  C A Meyers; W A Murphy; T W Redding; D H Coy; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

6.  N-terminally extended somatostatin: the primary structure of somatostatin-28.

Authors:  L Pradayrol; H Jörnvall; V Mutt; A Ribet
Journal:  FEBS Lett       Date:  1980-01-01       Impact factor: 4.124

7.  Stimulation of chloride secretion by P1 purinoceptor agonists in cystic fibrosis phenotype airway epithelial cell line CFPEo-.

Authors:  A C Chao; J B Zifferblatt; J A Wagner; Y J Dong; D C Gruenert; P Gardner
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

8.  Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Authors:  P Brazeau; W Vale; R Burgus; N Ling; M Butcher; J Rivier; R Guillemin
Journal:  Science       Date:  1973-01-05       Impact factor: 47.728

9.  Effect of somatostatin on myoelectrical activity of small bowel.

Authors:  P Thor; R Król; S J Konturek; D H Coy; A V Schally
Journal:  Am J Physiol       Date:  1978-09

10.  Somatostatin inhibits motilin-induced interdigestive contractile activity in the dog.

Authors:  H S Ormsbee; S L Koehler; G L Telford
Journal:  Am J Dig Dis       Date:  1978-09
View more
  6 in total

1.  Somatostatin sst2 receptor-mediated inhibition of parietal cell function in rat isolated gastric mucosa.

Authors:  M A Wyatt; E Jarvie; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Localization and pharmacological characterization of somatostatin sst2 sites in the rat cerebellum.

Authors:  C Piwko; V S Thoss; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

3.  Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst1 and sst2, in mouse fibroblast (Ltk-) cells.

Authors:  S W Castro; G Buell; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

4.  Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome.

Authors:  Alexandru Gaman; Maria Cristina Bucur; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2009-05-01       Impact factor: 4.409

5.  Further evidence from functional studies for somatostatin receptor heterogeneity in guinea-pig isolated ileum, vas deferens and right atrium.

Authors:  W Feniuk; J Dimech; E M Jarvie; P P Humphrey
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

6.  Somatostatin receptors mediating inhibition of basal and stimulated electrogenic ion transport in rat isolated distal colonic mucosa.

Authors:  E S McKeen; W Feniuk; P P Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.